Nasdaq to Delist Bio Green Med Solution's Preferred Stock; Common Stock Unaffected
Summary
Bio Green Med Solution's preferred stock will be delisted from Nasdaq due to non-compliance, but the company's common stock remains listed and unaffected.
Key Events
-
Preferred Stock Delisting Confirmed
Nasdaq notified the company that its 6% Convertible Exchangeable Preferred Stock (BGMSP) will be delisted for failing to meet the minimum $1 million Market Value of Publicly Held Shares requirement.
-
No Appeal Intended
The company does not plan to appeal Nasdaq's determination, confirming the delisting of the preferred stock.
-
Common Stock Unaffected
The delisting specifically applies to the preferred stock (BGMSP) and does not impact the listing of the company's common stock (BGMS) on The Nasdaq Capital Market.
-
Trading Suspension and OTC Transition
Trading of the preferred stock is expected to be suspended on March 23, 2026, with delisting on or after April 2, 2026. The preferred stock may then trade on the OTC Markets.
Analysis
This 8-K filing announces that Bio Green Med Solution, Inc.'s 6% Convertible Exchangeable Preferred Stock (BGMSP) will be delisted from The Nasdaq Capital Market due to failure to meet the minimum Market Value of Publicly Held Shares requirement. The company does not intend to appeal this decision, leading to a suspension of trading on March 23, 2026, and delisting on or after April 2, 2026. While the delisting of a security from a major exchange is a negative event, the filing explicitly states that the company's Common Stock (BGMS) remains listed on Nasdaq and is unaffected. Investors should note the reduced liquidity and prestige for the preferred stock, which is expected to trade on the OTC Markets.
At the time of this filing, BGMS was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.74 to $100.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.